Abstract
The number of allogeneic hematopoietic SCTs performed globally each year continues to increase, paralleled by an increased demand for donors of therapeutic cells. Donor characteristics and collection procedures have undergone major changes during recent decades, and further changes are foreseen. Information on short- and long-term donor outcomes is of crucial importance to ensure maximal donor safety and availability. Current data, predominantly from unrelated donors, give reliable information on the frequent early events associated with donation—most of them of mild-to-moderate intensity. Information on the type and relative risk of serious adverse reactions is more limited. Moreover, only few data exist on long-term donor outcome. On the basis of this need, recommendations for a minimum data set for prospective donor follow-up were developed in a workshop with the participation of an international group of investigators actively involved in allogeneic stem cell donation under the auspices of and approved by the Worldwide Network for Blood and Marrow Transplantation. Establishment of a standardized global follow-up for both, related and unrelated, donors will enable monitoring of the short- and long-term safety profiles of hematopoietic cell donation and form a solid basis for future donor selection and counseling.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Pasquini MC, Wang Z . Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides. 2010; Available at: http://www.cibmtr.org.
Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A et al. Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010; 303: 1617–1624.
Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011; 46: 485–501.
Buckner CD, Clift RA, Sanders JE, Stewart P, Bensinger WI, Doney KC et al. Marrow harvesting from normal donors. Blood 1984; 64: 630–634.
Anderlini P, Körbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903–908.
Shaw BE, Ball L, Beksac M, Bengtsson M, Confer D, Diler S et al. Clinical Working Group; Ethics Working Group of the WMDA. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. Bone Marrow Transplant 2010; 45: 832–838.
van Walraven SM, Nicoloso-de Faveri G, Axdorph-Nygell UA, Douglas KW, Jones DA, Lee SJ et al. WMDA ethics and clinical working groups. Family donor care management: principles and recommendations. Bone Marrow Transplant 2010; 45: 1269–1273.
World Health Organization. WHO guiding principles on human cell, tissue and organ transplantation. Transplantation 2010; 90: 229–233.
Miller JP, Perry EH, Price TH, Bolan CD, Karanes C, Boyd TM et al. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant 2008; 14 (9 Suppl): 29–36.
Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604–3611.
Hölig K, Kramer M, Kroschinsky F, Bornhäuser M, Mengling T, Schmidt AH et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757–3763.
Favre G, Beksaç M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al. European Group for Blood and Marrow Transplantation (EBMT). Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003; 32: 873–880.
Bredeson C, Leger C, Couban S, Simpson D, Huebsch L, Walker I et al. An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant 2004; 10: 405–414.
Tassi C, Tazzari PL, Bonifazi F, Giudice V, Nannetti A, Ricci F et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 2005; 36: 289–294.
de la Rubia J, de Arriba F, Arbona C, Pascual MJ, Zamora C, Insunza A et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008; 93: 735–740.
Horowitz MM, Confer DL . Evaluation of hematopoietic stem cell donors. Hematology Am Soc Hematol Educ Program 2005;, 469–475.
Confer DL, Miller JP, Chell JW . Bone Marrow and peripheral blood cell donors an donor registries. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds). Thomas’ Hematopoietic Cell Transplantation. 4th edn. Blackwell Publishing, John Wiley & Sons Ltd, Chichester, West Sussex, UK, 2009, pp 544–558.
Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94–101.
Kodera Y, Yamamoto K, Kato S, Harada M, Kanda Y, Hamajima N et al. Safety and Risk of Allogeneic Peripheral Blood Stem Cell Donation: The Comprehensive Report of Nation-Wide Consecutively Pre-Registered 3,264 Family Donor Survey in 10years Project by Japan Society for Hematopoietic Cell Transplantation, ASH. 2010 Poster 1180.
Niederwieser D, Gentilini C, Hegenbart U, Lange T, Moosmann P, Pönisch W et al. Transmission of donor illness by stem cell transplantation: should screening be different in older donors? Bone Marrow Transplant 2004; 34: 657–665.
Sacchi N, Costeas P, Hartwell L, Hurley CK, Raffoux C, Rosenmayr A et al. Quality Assurance and Clinical Working Groups of the World Marrow Donor Association. Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health. Bone Marrow Transplant 2008; 42: 9–14.
Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642–650.
Goldman JM, Madrigal JA, Pamphilon D . Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol 2006; 135: 651–652.
Confer DL, Miller JP . Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 77–78.
Bacher U, Zander AR . Long-term safety of filgrastim (rhG-CSF) administration: application of haematopoietic growth factors in healthy individuals. Br J Haematol 2007; 137: 78–79.
Anderlini P, Champlin RE . Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008; 111: 1767–1772.
Tagliari C, Florêncio R, Ostronoff M . Fatal complication of peripheral blood stem cell (PBSC) donor after granulocyte-colony stimulating factor (G-CSF) stimulation. ISH. 2010; Poster 192.
Pamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J . The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion 2008; 48: 1495–1501.
Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32: 31–34.
Hernández JM, Castilla C, Gutiérrez NC, Isidro IM, Delgado M, de las Rivas J et al. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005; 19: 1088–1091.
Hirsch B, Oseth L, Cain M, Trader E, Pulkrabek S, Lindgren B et al. Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood 2011; 118: 2602–2608.
Schmidt AH, Mengling T, Pingel J, Rall G, Ehninger G . Follow up of 12559 unrelated donors of peripheral blood stem cells or bone marrow. ASH 2010.
Hasenclever D, Sextro M . Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17 (Suppl 2): S28–S30.
Jin P, Wang E, Ren J, Childs R, Shin JW, Khuu H et al. Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med 2008; 6: 39.
Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S et al. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica 2008; 93: 347–355.
Donahue RE, Jin P, Bonifacino AC, Metzger ME, Ren J, Wang E et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood 2009; 114: 2530–2541.
Bortin MM, D'Amaro J, Bach FH, Rimm AA, van Rood JJ . HLA associations with leukemia. Blood 1987; 70: 227–232.
Wang SS, Slager SL, Brennan P, Holly EA, De Sanjose S, Bernstein L et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 109: 3479–3488.
Kroschinsky F, Hundertmark J, Mauersberger S, Hermes M, Poppe-Thiede K, Rutt C et al. Severe autoimmune hyperthyroidism after donation of growth factor-primed allogeneic peripheral blood progenitor cells. Haematologica 2004; 89: ECR05.
Martino M, Console G, Dattola A, Callea I, Messina G, Moscato T et al. Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. Bone Marrow Transplant 2009; 44: 163–168.
Nicolini FE, Wattel E, Michallet AS, Bourgeot JP, Tremisi JP, Hequet O et al. Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion. Exp Hematol 2004; 32: 1033–1039.
Miller AB, Hoogstraten B, Staquet M, Winkler A . Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
http://www.worldmarrow.org/ see adverse events.
Leitner GC, Baumgartner K, Kalhs P, Biener D, Greinix HT, Hoecker P et al. Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study. Bone Marrow Transplant 2009; 43: 357–363.
Machaczka M, Kalaitzakis E, Eleborg L, Ljungman P, Hägglund H . Comparison of general vs regional anaesthesia for BM harvesting: a retrospective study of anaesthesia-related complications. Bone Marrow Transplant 2010; 45: 53–61.
Jeger A, Favre G, Lutz JM, Stern M, Usel M, Rovo A et al. Tumor incidence in related hematopoietic stem cell donors. Bone Marrow Transplant 2011; 46: 1240–1244.
Al-Ali HK, Bourgeois M, Krahl R, Edel E, Leiblein S, Poenisch W et al. The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2011; 46: 1296–1302.
Confer DL, Shaw BE, Pamphilon DH . WMDA guidelines for subsequent donations following initial BM or PBSCs. Bone Marrow Transplant 2011; 46: 1409–1412.
O’Donnell PV, Pedersen TL, Confer DL, Rizzo JD, Pulsipher MA, Stroncek D et al. Donor Health and Safety Working Committee from Center for International Blood and Marrow Transplant Research (CIBMTR). Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. Blood 2010; 115: 5097–5101.
Acknowledgements
This work was supported by the Swiss Blood Stem Cells (SBSC), generously supporting the organization of the meeting in Bern, and a grant from the Swiss National Research Foundation (406340-128111).
Author contributions: JPH, SMvW, NW, MB, HH, GNdF, AHS, MF, AG and DC attended the workshop and wrote the paper. BES, AM, JS, MDA, DW, MMH, HG, DW and YK contributed the comments and wrote the paper.
Participants of the donor outcome workshop in alphabetical order: F Audat (France Greffe de Moelle), L Ball (LUMC), M Bengtsson (Tobias Registry), L Brezinova (Czech Stem Cells Registry), E Buhrfeind (SBSC), D Confer (NMDP/CIBMTR), M Fechter (Europdonor), A Gratwohl (University Hospital Basel), H Hägglund (Karolinksa University Hospital, Huddinge/Nordic donor registry), J Halter (University Hospital Basel), R King (NMDP/CIBMTR), E Korthof (LUMC), E Lawlor (IBTS), E Marry (France Greffe de Moelle), T Mengling (DKMS), J Ng-McClelland (CW Bill Young DOD Marrow Donor Program), G Nicoloso de Faveri (SBSC), S Rajadhyasksha (Tata Memorial Hospital), A Rosenmayr (Austrian Bone Marrow Registry), M Reti (Szent Istvan and Szent Laszlo University hospital Budapest), AH Schmidt (DKMS), C Tassi (University Hospital Bologna), SM van Walraven (Europdonor, WMDA), N Worel (Medical University of Vienna), L Zahlavova (Czech Stem Cells Registry)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that they have no conflict of interest.
Additional information
Supplementary Information accompanies the paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Halter, J., van Walraven, S., Worel, N. et al. Allogeneic hematopoietic stem cell donation—standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transplant 48, 220–225 (2013). https://doi.org/10.1038/bmt.2012.119
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.119
Keywords
- donor outcome
- global donor follow-up
- serious adverse reactions
- minimal data set
- WBMT
This article is cited by
-
Protection of haematopoietic progenitor cell donors: an updated overview of the European landscape
Bone Marrow Transplantation (2023)
-
Severe short-term adverse events in related bone marrow or peripheral blood stem cell donors
International Journal of Hematology (2023)
-
Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors – first 10 years of prospective donor follow-up of Swiss donors
Bone Marrow Transplantation (2022)
-
Hematopoietic cell transplant nurse coordinators’ perceptions of related donor care: a European survey from the EBMT Nurses Group
Bone Marrow Transplantation (2020)
-
Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation
Science China Life Sciences (2020)